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CYCLOSPORINE (Cy A)-induced pseudo-graft-ver-
sus-host disease (GVHD) developing in syngeneic 
rat bone marrow chimeras has features resembling classi-
cal acute and later chronic GVHD in the fully allogeneic 
bone marrow chimera. 1 These features develop in the 
early post-CyA period, and usually result in a mild, acute 
form of GVHD, followed by a more chronic autoimmune-
like syndrome in a high percentage of animals, particularly 
with high doses of Cy A. 1 Cy A-induced thymic changes, 
which include disruption of thymocyte maturation while 
on therapy, are thought to be the mechanisms responsible 
for these effects following the discontinuation of Cy A 
therapy. I Since FK 506, like CyA. affects the thymic 
microenvironment.2 we decided to observe the nature of 
any pseudo-GVHD reactions induced by the abrupt assa-
tion of FK 506 therapy following syngeneic BMT in the 
Lewis rat. 
MATERIALS AND METHODS 
Animals 
Male Lewis rats (Harlan Sprague Dawley, Indianapolis. Ind). ages 
6 to 8 weeks, were used in all experiments. Animals were 
maintained in a laminar flow caging system (Thorens Caging 
Systems), given acidified water containing tetracycline hydrochlo-
ride (100 mglL) and neomycin sulfate (10 mglL) and fed rat chow 
ad libitum. 
Immunosuppressants 
FK 506 was a gift from Fujisawa Pharmaceutical Co (Osaka. 
Japan). The powder with carrier solvent. HCO-60 and o-mannitol 
was diluted in normal saline for 1M injection. FK 506 was given 
once per day unless otherwise specified. 
BMT and GVHD 
Animals were transplanted in accordance with our previously 
described protocol. 3 Briefly. bone marrow was harvested from 
femurs and tibias of donor Lewis animals. washed and resus-
pended in Hanks' balanced salt solution, supplemented with 
gentamycin (50 mglmL). A total of60 x 106 8M cells were infused 
to lethally irradiated (1000 rad) Lewis recipients via the penile vein 
2 hours following irradiation. All animals received antibiotics in 
the immediate postoperative period. Lethally irradiated animals 
who received no marrow replacement, served to test adequacy of 
the preparative regime. Clinical GVHD was assessed in all ani-
mals on a daily basis. Both clinical and histological GVHD were 
defined according to previously described criteria from our insti-
tution. 3 
Study Design 
Groups of 8 rats were treated with various doses of FK 506 for 
between 21 and 28 days following BMT, starting on the day of 
Table 1. Group Assignments 
FK 506 (mglkg Treatment 
GI'OUll Reconstilution per day) Period (d) 
A Lewis 1.0 21 
B Lewis 0.5 28 
C Lewis 0.25 28 
BMT. The duration of therapy, dose of FK 506, and group 
assignments are as shown in Table I. The incidence of GVHD. 
mean GVHD-free interval. and overall survival were assessed for 
each group. 
RESULTS 
The type. onset of GVHD, and survival consequent upon 
the abrupt cessation of FK 506 at different times after 
syngeneic bone marrow transplantation in our rat bone 
chimeras are shown in Table 2. All irradiation controls 
died within 12 days of irradiation. 
In all groups, at least 75% of animals developed acute 
GVHD, as evidenced by dermatitis, red ears. and unkempt 
appearance. Acute GVHD increased with increasing doses 
of FK 506 (Table 2). The acute GVHD-free interval was, 
however. prolonged at higher FK 506 doses. and ranged 
from 40 to 55 days following BMT. The number of animals 
that developed a more severe. acute GVHD reaction, 
which led to the early features of chronic GVHD. were 
between 60% and 75%. after mean times ranging from 65 to 
78 days after BMT. 
Overall survival in the syngeneic chimeras did not fall 
Table 2. 
Percent MeanTmeto 
WIIh AculeGVHD Mean Time to Percent 
Acute (Days After ChrOnic GVHD Survival 
Group GVHD BMl) (Days After BMT) Posnransplant 
A 90 40± 3.0 65 ± 5.3 90 
B 80 55± 2.8 71 ± 6.9 100 
C 75 49 ± 2.9 78 ± 6.9 100 
All values are means ~ SEM. 
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below 90% at the end of the follow-up period (Table 2), 
which was 90 days from BMT. The 10% mortality in group 
A was related to poor general condition of these animals at 
the time of development of the chronic syndrome. 
DISCUSSION 
We have shown that FK 506 can induce a form of pseudo-
GVHD. The histological features confirm our clinical 
impressions that the nature of the induced GVHD is severe 
in the syngeneic recipients and affects survival at high 
doses. Interestingly, in allogeneic recipients, this syn-
drome is fatal in a high percentage of animals when a high 
dose of FK 506 is given for a relatively long period and 
then stopped (data not shown). The mechanisms shown to 
be responsible for the development ofCyA-induced pseu-
do-GVHD are related to how CyA affects the thymic 
3235 
microenvironment and thtmocyte maturation; ie. it inhib-
its the production of single positive mature thymocytes 
from the double-positive thymocyte stage.4 FK 506 also 
causes this defect. This pseudo-GVHD compares well 
with that described with CyA. It is, however. more severe 
in terms of severity of subsequent pseudo-GVHD. and this 
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